Dimitry Nuyten

Director Técnico/Científico/I+D en ARCUS BIOSCIENCES, INC. .

Fortuna: 203 569 $ al 30/04/2024

48 años

Health Technology

Consumer Services

Cargos activos de Dimitry Nuyten

Empresas	Cargo	Inicio	Fin
ARCUS BIOSCIENCES, INC.	Director Técnico/Científico/I+D	01/08/2022	-

Empresas	Cargo	Inicio	Fin
NEKTAR THERAPEUTICS	Director Técnico/Científico/I+D	19/07/2021	01/04/2022
PFIZER, INC.	Corporate Officer/Principal	01/07/2013	01/03/2019
BRISTOL-MYERS SQUIBB COMPANY	Director Técnico/Científico/I+D	01/03/2008	01/06/2013
CHINOOK THERAPEUTICS, INC.	Director Técnico/Científico/I+D	22/04/2019	-

University of Groningen	Doctorate Degree
University of Amsterdam	Doctorate Degree

Internacional

Estados Unidos	6
Países Bajos	3

Operativa

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	2
Corporate Officer/Principal	1

Sectorial

Health Technology	6
Consumer Services	3

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	4
PFIZER, INC.	Health Technology
BRISTOL-MYERS SQUIBB COMPANY	Health Technology
NEKTAR THERAPEUTICS	Health Technology
ARCUS BIOSCIENCES, INC.	Health Technology

Empresas privadas	1
Aduro BioTech, Inc. Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.	Health Technology

Empresas privadas

Health Technology